Basic info.

CAS: 129453-61-8

Alias: Faslodex

Molecular Fomular: C32H47F5O3S

Molecular Weight: 606.77

Density: 1.201 g/cm3

Melting Point: 104-106

Boiling Point: 674.8 ° C at 760 mmHg

Appearance: White powder

Usage: Antineoplastic (hormonal) 

Assay: 99% min.

Packing: 10 grams/foil bag

Grade : Pharmaceutical Grade

Storage: Shading, confined preservation

Delivery time :within 12 hours upon receipt of payment

Delivery: EMS, DHL, TNT, FedEx, UPS

Description:

Faslodex, AstraZeneca is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works by down-regulating the estrogen receptor.

Fulvestrant Acetate is a selective estrogen receptor down-regulator (SERD).

Fulvestrant Acetate is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. The dosing schedule for fulvestrant remains under investigation in an attempt to optimize its effectiveness.

Applications:

Many breast cancers are stimulated to grow by the female sex hormones oestrogen and progesterone. These breast cancers are called hormone sensitive or hormone receptor positive. Drugs that block the effects of these hormones can slow or stop the growth of the breast cancer cells. Fulvestrant stops oestrogen getting to the cancer cells by blocking oestrogen receptors and reducing the number of receptors the cancer cell has.

Fulvestrant (Faslodex, AstraZeneca) is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works by down-regulating the estrogen receptor.

Fulvestrant is a selective estrogen receptor down-regulator (SERD). Fulvestrant is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. The dosing schedule for fulvestrant remains under investigation in an attempt to optimize its effectiveness.